Cetuximab (Erbitux)

A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors.

Also Known As:

Networked: 5272 relevant articles (881 outcomes, 1653 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Ciardiello, Fortunato: 59 articles (03/2022 - 08/2002)
2.	Lenz, Heinz-Josef: 48 articles (01/2022 - 09/2004)
3.	Ferris, Robert L: 43 articles (01/2022 - 12/2007)
4.	Grandis, Jennifer R: 43 articles (11/2021 - 09/2006)
5.	Tabernero, Josep: 42 articles (04/2022 - 08/2005)
6.	Heinemann, Volker: 38 articles (01/2022 - 02/2007)
7.	Stintzing, Sebastian: 34 articles (01/2022 - 03/2011)
8.	Van Cutsem, Eric: 33 articles (01/2021 - 07/2004)
9.	Siena, Salvatore: 32 articles (01/2021 - 07/2004)
10.	Tejpar, Sabine: 31 articles (01/2020 - 08/2007)

Related Diseases

1.	Colorectal Neoplasms (Colorectal Cancer) 10/01/2016 - "Adding cetuximab to first-line FOLFIRI in the phase 3 CRYSTAL trial significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with KRAS wild-type (wt) or RAS wt metastatic colorectal cancer (mCRC). " 01/01/2013 - "In the CRYSTAL study adding cetuximab to first-line FOLFIRI significantly improved outcome in patients with KRAS wild-type metastatic colorectal cancer. " 04/01/2010 - "In subgroup analysis, in colorectal cancer, there was a significant improvement of PFS (0.72, 0.66-0.78), OS (0.90, 0.81-1.00), and ORR in the cetuximab group (1.36, 1.15-1.60). " 07/01/2014 - "The NCIC CTG/AGITG CO.17 trial demonstrated that cetuximab monotherapy improved overall and progression-free survival (OS and PFS) in patients previously treated for advanced colorectal cancer. " 01/01/2023 - "Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location."
2.	Neoplasms (Cancer) 01/01/2010 - "The mice receiving MnSOD-PL, C225, TPZ plus 14 Gy had the best outcome with 0.7+/-0.1 fold increase in tumor volume by 10 days (p=0.015) compared to irradiation only. " 08/01/2021 - "Besides, the anti-tumor efficacy of C-CUS245C was remarkably more potent than that of Cetuximab, CUS245C, and C + CUS245C (P < 0.001). " 01/15/2005 - "In nude mice bearing EGFR-expressing, cetuximab-sensitive, NSCLC cell line xenografts, cetuximab plus radiation induced a marked improvement in tumor growth inhibition over either agent alone. " 04/15/2022 - "Cetuximab (CTX) is known to have cytotoxic effects on several human cancer cells in vitro; however, as CTX is poorly water soluble, there is a need for improved formulations can reach cancer cells at high concentrations with low side effects. " 01/01/2020 - "TLR7/8 agonist-loaded NP treatment significantly enhanced the antitumor efficacy of cetuximab and an anti-HER2/neu antibody in mouse tumor models. "
3.	Squamous Cell Carcinoma of Head and Neck 04/03/2012 - "Besides its proven efficacy in locally advanced and incurable HNSCC, cetuximab has the distinct advantage of having a relatively tolerable side effect profile and not potentiating radiation toxicity. " 03/20/2011 - "Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck." 02/01/2015 - "The addition of cetuximab for the treatment of patients with locally advanced or recurrent/metastatic HNSCC has improved overall survival and locoregional control; however, responses are often modest, and treatment resistance is common. " 10/13/2023 - "These preclinical findings demonstrate that ML differentiation alone or coupled with either cetuximab-directed targeting or EphA2 CAR engineering were effective against HNSCCs and provide the rationale for investigating these combination approaches in early phase clinical trials for patients with HNSCC." 01/01/2019 - "Therefore, the identification of novel therapeutic approaches to enhance the clinical efficacy of cetuximab could lead to improved long-term survival for HNSCC patients. "
4.	Head and Neck Neoplasms (Head and Neck Cancer) 01/01/2006 - "Indeed, one of the more striking clinical results in this field has been recently achieved by combining an EGFR inhibitor (cetuximab) with radiation in the treatment of advanced head and neck cancer patients. " 03/01/2009 - "We discuss the results of the phase III EXTREME (Erbitux in First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer) trial. " 07/01/2016 - "Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer." 01/01/2015 - "Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients." 06/20/2023 - "This study examines treatment trends and survival effects of locally advanced head and neck cancer patients before and after Taiwan's National Health Insurance covered cetuximab. "
5.	Neoplasm Metastasis (Metastasis) 07/01/2020 - "In FIRE-3, resection of metastases was associated with improved post-best response survival, this effect originated predominantly from the cetuximab-based study arm." 04/14/2009 - "Initially unresectable metastases became resectable in one-quarter of patients, with a high number of complete resections, and these promising results formed the basis for the investigation of FOLFIRI with and without cetuximab in the phase III CRYSTAL trial." 12/01/2007 - "Cetuximab with FOLFIRI may be an effective and safe treatment option for downsizing unresectable colorectal liver metastases." 01/01/2018 - "We performed a phase I clinical trial to assess the safety and efficacy of in situ delivery of allogeneic NK cells combined with cetuximab in liver metastasis of gastrointestinal origin. " 01/01/2013 - "The literature does not support the routine use of cetuximab as the standard first-line treatment of colorectal liver metastases, rather highlighting the need for the optimization of treatment on an individual basis, especially depending on tumour KRAS status."

Related Drugs and Biologics

1.	Bevacizumab (Avastin)
2.	ErbB Receptors (EGF Receptor)
3.	Irinotecan (Camptosar)
4.	Fluorouracil (Carac)
5.	Monoclonal Antibodies
6.	Cisplatin (Platino)
7.	Panitumumab (Vectibix)
8.	Oxaliplatin (Eloxatin)
9.	Leucovorin (Folinic Acid)
10.	Platinum

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Radiotherapy
4.	Chemoradiotherapy
5.	Combination Drug Therapy (Combination Chemotherapy)